• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Supporting Musculoskeletal Health: Tending to Muscles, Joints, and Bones

    2023 Contract Manufacturing Survey

    Dosage and Delivery Innovations Help Manufacturers Meet Common Challenges

    A Paradigm Shift for Antioxidants?

    Manufacturing Dietary Supplements in Economic Uncertainty
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Glossary
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    'What’s Up With Supps' Event at Expo West Raises Over $8,000 for Vitamin Angels

    IRI and NPD Rebrand as Circana Following Merger

    ABC’s Sustainable Herbs Program Updates Sustainability and Regenerative Practices Toolkit

    HP Ingredients Introduces NuFemme, Herbal Blend for Women’s Hormonal Support

    World Economic Forum Names Sofia Elizondo of Brightseed a Young Global Leader
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    ABC’s Sustainable Herbs Program Updates Sustainability and Regenerative Practices Toolkit

    HP Ingredients Introduces NuFemme, Herbal Blend for Women’s Hormonal Support

    World Economic Forum Names Sofia Elizondo of Brightseed a Young Global Leader

    Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision

    Cucumber Extract May Improve Joint Function
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    'What’s Up With Supps' Event at Expo West Raises Over $8,000 for Vitamin Angels

    IRI and NPD Rebrand as Circana Following Merger

    ABC’s Sustainable Herbs Program Updates Sustainability and Regenerative Practices Toolkit

    World Economic Forum Names Sofia Elizondo of Brightseed a Young Global Leader

    Intake of Live Microbes from the Diet, Including Fermented Foods, Associated with Better Health
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    'What’s Up With Supps' Event at Expo West Raises Over $8,000 for Vitamin Angels

    HP Ingredients Introduces NuFemme, Herbal Blend for Women’s Hormonal Support

    World Economic Forum Names Sofia Elizondo of Brightseed a Young Global Leader

    Intake of Live Microbes from the Diet, Including Fermented Foods, Associated with Better Health

    Cucumber Extract May Improve Joint Function
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Bioenergy Life Science, Inc. (BLS)

    Chenguang Biotech Group Co., Ltd.

    KLK OLEO

    BGG Americas, Inc.

    Xsto Solutions
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Bioenergy Life Science, Inc. (BLS)

    Chenguang Biotech Group Co., Ltd.

    KLK OLEO

    BGG Americas, Inc.

    Xsto Solutions
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Regulatory Drumbeat Continues to Echo

    FDA’s latest actions exemplify how it views the dietary supplement industry.

    The Regulatory Drumbeat Continues to Echo
    Todd Harrison, Venable11.01.16
    The dietary supplement industry once again finds itself in the crosshairs of U.S. regulators. In August, FDA issued its revised draft guidance document regarding New Dietary Ingredient (NDI) notifications. Subsequently, the agency has requested comments related to its tentative conclusion that vinpocetine is not a dietary ingredient—regardless of the fact that FDA, on five previous occasions, had the opportunity to raise an issue regarding its regulatory status.

    Meanwhile, the New York Attorney General (AG) reached another settlement with a large dietary supplement company regarding supply chain integrity and DNA testing (NBTY, Inc.). And the Drug Enforcement Agency (DEA) attempted to schedule a benign herb (kratom) through its emergency scheduling process. Additional developments have included recent settlements out of the State Iowa AG office and the state of California.

    What do all of these situations have in common? The constant drumbeat from regulators has been that the industry is simply not doing enough to self-regulate. This overall perception has not changed, quite frankly, since the Dietary Supplement Health and Education Act (DSHEA) was passed in October 1994; but is this all the fault of industry, or do regulators bear responsibility in this process?

    FDA’s Inaction & Ambivalence
    From my perspective, while the industry has not always done its best to comply with the requirements of DSHEA, I would argue that a large part of the blame falls on regulators—FDA in particular. The new NDI draft guidance, the NY AG’s efforts on traceability, DEA’s misstep with kratom, and even the issues surrounding claims can be directly attributable to FDA’s general ambivalence—some would say outright hostility—toward the industry. One only needs to look at the timeline to figure out that many of these issues could have been avoided if FDA would have simply taken a more active approach toward regulating the industry in 1994.

    DSHEA became effective on Oct. 14, 1994; yet during the next 22 years, FDA rarely did anything with regard to supply chain integrity and new dietary ingredients. For instance, it should not take the NY AG to enter into agreements with GNC and NBTY to make it clear that ingredient manufacturers are an integral part of ensuring supply chain integrity.

    Indeed, the issue of identity testing should not start at the finished product manufacturing stage, but rather at the ingredient manufacturing stage. Especially with botanicals, the ingredient manufacturer is in better position to conduct the initial identity testing than the finished product manufacturer. Yet, FDA made a decision to exempt ingredient manufacturers from Part 111. To this day that decision is dumbfounding to me.

    FDA continues to ignore a citizen petition by the Organic & Natural Health Association that requested the agency bring ingredient manufacturers under Part 111, even though state AGs and members of Congress have called for the same. FDA could achieve this task in short order. Instead, the NY AG is making agreements with companies to make this happen; however, these companies by themselves can’t achieve the ultimate goal, as the ingredient manufacturing industry is not of an insignificant size. 

    New Dietary Ingredients
    First, in the immortal words of Green Bay Packers Quarterback Aaron Rodgers: r-e-l-a-x, Relax. The draft guidance is just that—a draft guidance document. Moreover, it only represents FDA’s current thinking on the matter and does not have the effect of law. Forget for a moment that FDA has no ability under the law to reject a notification or to approve new dietary ingredients; as stated in my last column, the document has fundamental issues that the agency still needs to work through (September 2016, “FDA Issues Revised Draft Guidance On New Dietary Ingredients”).

    With that said, if the agency had worked with industry in 1994-1995 on developing a positive list of ingredients, as well as a policy around what would be considered a new dietary ingredient—such as a substantial change in concentration of a particular ingredient—we would not be in a situation today where we need to determine what is rightfully an “old” dietary ingredient.

    Yet, it has taken FDA more than 22 years to determine that it should compile such a list, even though the industry had compiled a list back in the mid-1990s, which FDA has refused to adopt. The agency should start with that list and request information on ingredients that are not on the list. Yet, for whatever reason, FDA is simply rejecting this approach, which is nonsensical and feeds into the general perception that the industry can’t be trusted. FDA has reinforced this perception with vinpocetine. 

    Vinpocetine’s Regulatory Status
    As everyone knows, including FDA, there were no less than five new dietary ingredient notifications regarding vinpocetine without comment from the agency. Yet, even though this ingredient is reasonably expected to be safe, in what appears to be a purely political decision sparked by Senator Claire McCaskill (D-MO), FDA decided to dig up some old press releases regarding this ingredient. 

    The industry has a reason to take issue because FDA has, at a minimum, treated the new dietary ingredient notification as a quasi-approval process—if not an outright approval process—and the industry should have been able to rely on it when making decisions about whether to incorporate a new dietary ingredient into a finished dietary supplement. This is not a situation where an ingredient supplier was relying on a Generally Recognized As Safe (GRAS) self-determination, or use in the food supply to escape the notification process. Rather, the notification was actually filed and FDA had no comment.  “No comment” does not mean FDA agrees with the notice; however, given FDA’s propensity to question these notifications, it is absurd that the agency now has a concern, stating that because it believes vinpocetine is a synthetic ingredient, subject of an investigational new drug (IND) application and substantial, public clinical trials in the U.S. prior to its introduction as a dietary ingredient. 

    Putting aside the latter point, which poses significant issues, there is simply not justification for FDA’s position on synthetic botanicals or ingredients synthesized from botanicals. Nowhere in DSHEA or its legislative history does it indicate that synthetics are not permitted. Indeed, the catch-all provision of DSHEA regarding a “dietary substance” when viewed in light of the “new” dietary ingredient notification provisions clearly contemplates that new dietary substances would be developed. Otherwise, the new dietary ingredient notification provision would rarely be used, which was not the intent of Congress. 

    Moreover, the use of the term “substance,” rather than nutrient or nutritive, clearly indicates that Congress contemplated something other than one of the specific categories delineated in the definition of a dietary supplement. In other words, “substance” contemplates synthetic ingredients that may be developed. Thus, FDA’s position on synthetic botanicals is directly at odds with Congressional intent.

    Regardless, if we are going to treat the notification process as just that—a notification process—it is difficult to penalize the agency for not understanding that an IND and substantial, public clinical trials were conducted on an ingredient. 

    Moreover, it should be required for the notifier to certify that the ingredient was not the subject of the IND and clinical trials prior to the submission of the notification. With that said, FDA is treating this requirement as an absolute bar. However, that is simply not true. More specifically, FDA has the authority to permit its use as a dietary supplement if after notice and comment the agency finds the article can be lawfully marketed as a dietary supplement. (See Federal Food, Drug, and Cosmetic Act § 201(ff)(3)(B)(ii).)  

    Of particular importance in this instance, if the drug approval had already taken place under §201(ff)(3)(A), this option would not be available. In other words, Congress recognized that there may be instances where a substance is not approved because it did not help in the treatment of a disease but would have value to overall health and well-being as a dietary substance. Accordingly, we would hope FDA understands this important distinction and use its request for comments on vinpocetine to affirm its use as a dietary ingredient; there is no question that it has never been approved as a drug in the U.S., and it has a reasonable expectation of safety based on FDA’s own review.

    As an industry, we do need to do better. However, FDA needs to step up and understand that we cannot simply hit a reset button that suddenly sends us back to October 1994. FDA should affirm vinpocetine’s use as a dietary ingredient as permitted under the FFD&C Act, abandon its view on synthetics and bring ingredient manufacturers under Part 111.


    Todd Harrison
    Venable

    Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Dietary Supplements
    • Quality & Safety
    • Regulations
    • Testing
    Related Knowledge Center
    • Quality & Safety
    • Regulations
    • Dietary Supplements
    • Testing
    Suggested For You
    Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision
    Amazon Bans Dietary Supplements Containing NMN Amazon Bans Dietary Supplements Containing NMN
    Common Sense Solutions to Regulating Cannabis and CBD Common Sense Solutions to Regulating Cannabis and CBD
    Natural Products Association Blasts FDA for Punting CBD Issues to Congress Natural Products Association Blasts FDA for Punting CBD Issues to Congress
    FDA Denies CBD Petitions, Cites Safety Concerns, Looks to Congress for New Regulatory Pathway FDA Denies CBD Petitions, Cites Safety Concerns, Looks to Congress for New Regulatory Pathway
    Regulatory Challenges Persist for Dietary Supplement Stakeholders Regulatory Challenges Persist for Dietary Supplement Stakeholders
    What People Were Reading in November 2022 on NutraceuticalsWorld.com What People Were Reading in November 2022 on NutraceuticalsWorld.com
    FDA Warning Letters Take Aim at Foods and Beverages Containing CBD FDA Warning Letters Take Aim at Foods and Beverages Containing CBD
    NDI Déjà vu: Another Ingredient Falls Victim to FDA’s Interpretation of Drug Preclusion Clause NDI Déjà vu: Another Ingredient Falls Victim to FDA’s Interpretation of Drug Preclusion Clause
    New Dietary Ingredient (NDI) & NDI Notification New Dietary Ingredient (NDI) & NDI Notification
    Dietary Ingredient Dietary Ingredient
    Marine-Derived Collagen Peptides May Have Protective Properties in Gut Marine-Derived Collagen Peptides May Have Protective Properties in Gut
    ‘Prohibited Acts’ Provision Could Be Used to Target Law-Abiding Companies & Legit Dietary Ingredients ‘Prohibited Acts’ Provision Could Be Used to Target Law-Abiding Companies & Legit Dietary Ingredients
    Hofseth BioCare Gains NDI Acknowledgement for ProGo Bioactive Peptides Hofseth BioCare Gains NDI Acknowledgement for ProGo Bioactive Peptides
    ODSP Director Cara Welch Discusses Agency Priorities ODSP Director Cara Welch Discusses Agency Priorities

    Related Columns

    • Antioxidants | Dietary Supplements | Herbs & Botanicals | Regulations | Regulatory News | Vitamins
      Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision

      Disappearing Act: The Battle Over Dietary Supplement Ingredients and the Drug Exclusion Provision

      Increasingly, FDA has used this ‘race to market’ language of DSHEA to prevent or remove safe and legitimate dietary ingredients from commerce.
      By James J. Gormley, Gormley NPI Consulting 03.16.23

    • Dietary Supplements
      Amazon Bans Dietary Supplements Containing NMN

      Amazon Bans Dietary Supplements Containing NMN

      The decision followed FDA’s declaration that the ingredient was first authorized for investigation as a new drug.
      02.16.23

    • Dietary Supplements | Herbs & Botanicals | Mood Health & Sleep | Quality & Safety | Regulations
      Common Sense Solutions to Regulating Cannabis and CBD

      Common Sense Solutions to Regulating Cannabis and CBD

      Blake Ebersole, president and founder of NaturPro Scientific tells the ‘honest and unvarnished truth’ to his clients.
      By Sheldon Baker, Baker Dillon / Area Code 420 02.09.23


    • Dietary Supplements | Herbs & Botanicals | Regulations
      Natural Products Association Blasts FDA for Punting CBD Issues to Congress

      Natural Products Association Blasts FDA for Punting CBD Issues to Congress

      FDA rejected NPA’s petition that asked the agency to clear a regulatory pathway for CBD and to review safety data from cbdMD.
      By Sean Moloughney, Editor 01.27.23

    • Dietary Supplements | Herbs & Botanicals | Regulations
      FDA Denies CBD Petitions, Cites Safety Concerns, Looks to Congress for New Regulatory Pathway

      FDA Denies CBD Petitions, Cites Safety Concerns, Looks to Congress for New Regulatory Pathway

      In response letters, agency says NDI process not robust enough to ensure applicable safety standards are met.
      By Sean Moloughney, Editor 01.26.23

    Loading, Please Wait..
    Trending
    • Shiitake Mushroom Extract Appears Helpful In HPV Infections
    • The Functional Chocolate Company Launches Painfree Chocolate
    • HMB And Vitamin D Supplementation Linked To Reduction In Fat Stores
    • Amazon Bans Dietary Supplements Containing NMN
    Breaking News
    • House Reps Try Again to Regulate CBD and Other Hemp Derivatives as Dietary Ingredients
    • 'What’s Up With Supps' Event at Expo West Raises Over $8,000 for Vitamin Angels
    • IRI and NPD Rebrand as Circana Following Merger
    • ABC’s Sustainable Herbs Program Updates Sustainability and Regenerative Practices Toolkit
    • HP Ingredients Introduces NuFemme, Herbal Blend for Women’s Hormonal Support
    View Breaking News >
    CURRENT ISSUE

    March 2023

    • Supporting Musculoskeletal Health: Tending to Muscles, Joints, and Bones
    • Dosage and Delivery Innovations Help Manufacturers Meet Common Challenges
    • 2023 Contract Manufacturing Survey
    • Manufacturing Dietary Supplements in Economic Uncertainty
    • Beyond Antioxidants: The Power of Berries
    • A Paradigm Shift for Antioxidants?
    • Ayana Bio on Path to Scale Bioactives Derived from Plant Cell Cultures
    • Nuritas: Leveraging Artificial Intelligence to Speak the Language of Life
    • Dietary Supplement Quality Assurance Programs Critical to Natural Products Industry Success
    • Innovation in Nutraceuticals: Dose Forms and Application Science Help Meet Consumer Demand
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    'What’s Up With Supps' Event at Expo West Raises Over $8,000 for Vitamin Angels
    IRI and NPD Rebrand as Circana Following Merger
    ABC’s Sustainable Herbs Program Updates Sustainability and Regenerative Practices Toolkit
    Coatings World

    Latest Breaking News From Coatings World

    BASF Invests in Expansion of Polymer Dispersions Plant in Daya Bay, China
    Stahl Completes Acquisition of ICP Industrial Solutions Group
    Interpon Powder Coatings on Dubai’s Latest Luxury Hotel ​
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    David Schnur Associates Adds ERI Group to Its Network of Partners
    BlackHägen Design Promotes Jeff Morang to Director of Human Factors Engineering
    Great Speech Wins First Place at ATA 2023 Innovator’s Challenge
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioNTech, OncoC4 Partner to Develop mAb Candidate ONC-392 in Cancer
    FLAMMA to Invest $200M Over the Next Three Years
    Pii Forms New Leadership Team
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Selena Gomez Becomes Most-Followed Woman on Instagram
    Former Estée Lauder Execs Join Stila Cosmetics' Advisory Board
    Ole Henrickson's Eye Stick is Made from Limestone
    Happi

    Latest Breaking News From Happi

    L’Oréal Invests in Geno-led Venture for Biotech Ingredients
    Saltair Adds Santal Bloom Body Oil to Personal Care Collection
    Fredericksburg Farms Recalls Scented Candles with Glass Lids
    Ink World

    Latest Breaking News From Ink World

    Kodak Reports 4Q, Full-Year 2022 Financial Results
    Fujifilm Releases Uvijet HZ Thermoforming Ink for Acuity Prime Series
    Arkema Bolsters Its CSR Efforts in China
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Schreiner PrinTrust supplies RFID-enabled labels for seventhings
    McDonald’s to publish report on reusable packaging
    Registration opens for FSEA's Print Embellishment Conference
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: TerraCycle Launches Diaper Program, Ahlstrom to Divest or Shutter Stenay Plant & More
    Mativ Names CFO
    Indorama Ventures, Polymateria Partner on Biotransformation Technology
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Receives Expanded Indications for Precice Limb Lengthening Solution
    Alex Jahangir Receives Highest Leadership Award From AAOS
    ODT's Most-Read Stories This Week—March 18
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Jabil Posts Second Quarter 2023 Results
    Optomec Mourns Unexpected Loss of CEO Dave Ramahi
    Zebra Technologies Names Rob Armstrong Chief Marketing Officer

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login